Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies
Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases.
BioShin is a clinical stage biopharmaceutical company.
Rain Oncology is a operator of a clinical stage biotechnology company.
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
New Horizon Health is a bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes.
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Akouos is a biotechnology company focusing on restoring and preserving hearing.
NuVera Medical is a medical device company
Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 16 different industry categories.
Among tracked funding rounds, Turning Point Therapeutics received $460.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $23.5B.
Cormorant Asset Management's average investment size is $137.2M across its portfolio of 209 companies.
Recent Cormorant Asset Management portfolio additions include NiKang Therapeutics, Elpiscience Biopharmaceuticals, Renovia, Graphite Bio, DTx Pharma. These companies were founded in 2020 or later.